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Objective. We conducted this study to 
evaluate the clinical outcomes of patients 
with severe sepsis and septic shock who 
were treated with ketamine for endotra-
cheal intubation.
Methods. A single-center, retrospective 
study was carried out to compare the out-
comes of patients with severe sepsis and 
septic shock who received a ketamine or 
non-ketamine agent for rapid sequence 
intubation (RSI). We analyzed the sepsis 
registry for adult patients who presented to 
the emergency department (ED), met the 
criteria for severe sepsis or septic shock, 
and underwent endotracheal intubation 
between August 2008 and March 2014. 
The primary outcome was 28-day mortal-
ity. We performed a multivariable logistic 
regression analysis to assess the association 
between ketamine use for intubation and 
28-day mortality. 
Results. In all, 170 patients were intubated 
during the study period. Of the eligible 
patients, 95 received ketamine and 75 re-
ceived a non-ketamine agent. The 28-day 
mortality of the ketamine group was not 
significantly different from that of the non-
ketamine group (38% vs. 40%, respectively, 
P=0.78). The unadjusted odds ratio (OR) 
of ketamine use for 28-day mortality was 
0.92 (95% CI: 0.49–1.70, P=0.78). The as-
sociation remained insignificant after ad-
justing for age, gender, malignancy, initial 
lactate level on ED admission, time to first 
antibiotic administration, Acute Physiolo-
gy and Chronic Health Evaluation II score 
on admission day, and propensity score re-
garding ketamine use (adjusted OR: 1.09; 
95% confidence interval [CI]: 0.49–2.40; 
P=0.84). Initial serum lactate on ED ad-
mission was the only significant predictive 
factor of 28-day mortality (adjusted OR: 
1.23; 95% CI: 1.10–1.38; P<0.01).
Conclusions. For patients with severe sep-
sis and septic shock who were intubated 
using RSI, we found no significant differ-
ence in 28-day mortality between those 
who received ketamine as a sedative agent 
and those who received alternative seda-
tives.
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INTRODUCTION
Severe sepsis and septic shock are life-
threatening conditions frequently com-
plicated by airway compromise and acute 
respiratory failure. According to recent 
large studies, approximately 30%–95% of 
critically ill patients with sepsis require 
intubation. (1-5) Endotracheal intubation 
with mechanical ventilation is a life-saving 
intervention used in such situations to 
support the increased work of breathing, 
improve oxygenation and ventilation, and 
secure a patent airway. 
Several studies have demonstrated that the 
rapid sequence intubation (RSI) technique, 
in which a potent sedative agent, followed 
by a rapidly acting neuromuscular block-
ing agent administered to facilitate en-
dotracheal intubation, provides optimal 
intubating conditions while minimizing 
untoward complications even in emer-
gency airway situations. (6,7) However, the 
choice of appropriate sedatives for RSI in 
critically ill patients with sepsis is a chal-
lenging task. Such patients are likely to have 
limited physiologic reserves and might be 
very sensitive to sedatives; even low doses 
of sedatives can have a deleterious effect 
on patient hemodynamics. Among several 
sedatives, etomidate has been widely used 
for RSI in critically ill patients because of 
its predictable onset and duration of action 
and minimal effects on hemodynamic in-
dices. However, concerns have been raised 
regarding potential detrimental effects of 
etomidate-related adrenal insufficiency in 
septic patients, although the causal rela-
tionship between adrenal insufficiency and 
outcome remains inconclusive. (8) 
Ketamine has received renewed attention 
in the emergency airway arena because it 
shares similar pharmacologic features (ex-
cept adrenal suppression) with etomidate. 
(9) Although the current opinion is that 
ketamine is a good alternative to etomidate 
for intubation in critically ill patients with 
sepsis, few studies have specifically investi-
gated the outcomes of patients with severe 
sepsis or septic shock treated with keta-
mine. (10) Therefore, we conducted this 
study to evaluate the clinical outcomes of 
patients with severe sepsis or septic shock 
who received ketamine during endotra-
cheal intubation. 
METHODS
A retrospective, single-center cohort 
study of patients with severe sepsis or sep-
tic shock who were intubated using the 
RSI technique was conducted at Samsung 
Medical Center (a 1,960-bed, university-
affiliated tertiary teaching hospital), lo-
cated in a metropolitan city. The study 
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was approved by the Institutional Review 
Board, and informed consent was waived 
because it was a retrospective study and 
no intervention was performed. 
Patient inclusion criteria
Patients who met all of the following crite-
ria were included for analysis: 1) 18 years 
of age or older; 2) those who presented 
to the emergency department (ED) with 
severe sepsis with serum lactate concen-
tration ≥ 4 mmol/l or septic shock; and 
3) patients who underwent RSI within 72 
hours of ED administration. The decision 
to intubate was based on clinical evidence 
of respiratory distress (e.g., the use of ac-
cessory muscles during respiration) and/
or altered mental status requiring airway 
protection. The selection of intubating 
devices and medications was entirely de-
pendent on the preferences of the op-
erator. After verification of proper tube 
placement, post-intubation management, 
including applying the ventilator, was con-
ducted according to standard protocol. 
Definition
The definition of sepsis used in this study 
was defined by the American College of 
Chest Physicians/Society of Critical Care 
Medicine Consensus Conference. (11) Se-
vere sepsis was described as sepsis associ-
ated with acute organ dysfunction. Septic 
shock was defined as sepsis that presented 
with hypotension (systolic blood pressure 
<90 mmHg, mean arterial pressure [MAP] 
<60 mmHg, or a reduction in systolic 
blood pressure > 40 mmHg from baseline) 
despite adequate fluid resuscitation (30 
ml/kg) in the absence of other causes of 
hypotension. 
Body mass index (BMI) was used to clas-
sify patients as underweight (BMI <18.5 
kg/m2), normal weight (18.5≤ BMI <25 
kg/m2), or overweight (BMI ≥25 kg/m2). 
Time to antibiotic administration was de-
fined as the time from ED arrival until the 
initiation of the first antibiotic administra-
tion. 
Data collection and outcome measures
Data on patients who met the criteria for 
severe sepsis or septic shock on ED arrival 
were prospectively collected from August 
2008 to March 2014, including every intu-
bation attempt performed in the ED and 
intensive care unit (ICU). The data had 
been previously used in other studies of 
severe sepsis and septic shock. (12-14) The 
protocol for the management of patients 
with severe sepsis or septic shock was 
based on the protocol by Rivers et al. and 
international guidelines (2008 and 2012 
Surviving Sepsis Campaign (SSC) Guide-
lines). Patients were treated according to 
the protocol, and the process was super-
vised by a board-certified emergency phy-
sician or intensivist. The following data 
were retrieved from a sepsis registry and 
electronic medical records: general char-
acteristics of patients, including gender, 
age, body mass index, and comorbidity, 
as well as laboratory data including ini-
tial serum lactate, source of infection, and 
sepsis interventions such as fluid manage-
ment. We also collected data related to the 
intubation procedure as follows: physi-
ologic measures before intubation, drug 
administration for RSI, and vasopressor 
and corticosteroid use. The Sequential Or-
gan Failure Assessment (SOFA) score and 
the Acute Physiology and Chronic Health 
Evaluation (APACHE) II score at baseline 
were calculated at the time of diagnosis of 
severe sepsis or septic shock to determine 
the estimated disease severity.  
The primary outcome of the study was 28-
day mortality. The secondary outcomes 
were overall in-hospital length of stay 
(LOS), ICU LOS, ventilator days, and in-
hospital mortality.
Statistical analysis
The included patients were categorized 
into either a ketamine group (those who 
received ketamine) or a non-ketamine 
group (those who received non-ketamine 
agents, such as etomidate or midazolam) 
based on the type of sedative agent used 
for RSI. Data are presented as the median 
with interquartile range (IQR) for numer-
ic data and as number with percentage for 
categorical data. The Wilcoxon rank sum 
test was used for continuous variables, 
while the Chi-square test was employed 
for categorical variables. 
Multiple logistic regression models were 
constructed to predict ketamine use for 
endotracheal intubation. In these models, , 
we adjusted the variable for different base-
line characteristics including presence of 
malignancy, initial mean arterial pressure, 
any vasopressor use before intubation, 
time to antibiotic administration, location 
of intubation, and reasons for intubation. 
In addition, other multiple logistic regres-
sion models were constructed to assess 
the association between ketamine use and 
28-day mortality. Two models were devel-
oped. Model 1 was adjusted for age, gen-
der, malignancy, initial lactate level, time 
to antibiotic administration and severity 
of illness as assessed by the APACHE II 
score. In Model 2, the propensity score re-
garding ketamine use was added in addi-
tion to the adjusting factors used in Model 
1. Initial MAP, time to antibiotic adminis-
tration, any vasopressor use before intuba-
tion and location of intubation were used 
for calculating the propensity score. The 
goodness-of-fit of the final logistic regres-
sion model was assessed using the Hos-
mer-Lemeshow test and Nagelkerke’s R2. 
Area under the receiver operating charac-
teristic (AUC) curve was used to indicate 
classification accuracy. The results were 
presented as the adjusted odds ratio (OR) 
with a 95% confidence interval (CI). A 
P-value less than 0.05 was considered sta-
tistically significant. STATA 13.0 (STATA 
Corporation, College Station, TX, USA) 
was used for statistical analyses.
RESULTS
Comparison of baseline characteristics
A total of 170 patients were intubated 
during the study period. Of the eligible 
patients, 95 received ketamine and 75 re-
ceived a non-ketamine agent. The sedative 
agents used in the non-ketamine group 
were etomidate (n=40) and midazolam 
(n=35). The baseline characteristics of 
each group are described in table 1. Age, 
gender, BMI and suspected infection fo-
cus were not different between the groups. 
Patients with malignancy presented more 
frequently in the ketamine group than in 
the non-ketamine group. The ketamine 
group showed a significantly lower MAP 
on ED arrival compared to the non-keta-
mine group. Accordingly, any vasopressor 
use before intubation was significantly 
higher in the ketamine group than it was 
in the non-ketamine group (60% vs. 35% 
respectively, P <0.01). Initial serum lactate 
and APACHE II scores were not related to 
the type of sedative agent used. 
Variables associated with intubation
A comparison of the variables associated 
with intubation is shown in table 2. Im-
mediately before intubation, vital signs, 
including MAP, heart rate, respiratory rate 
and peripheral capillary oxygen saturation 
were not different between the two groups. 
The median time to intubate following ED 
admission was 6.9 (IQR: 2.6 – 22.5) hours 
and was not significantly different be-
tween the two groups (P=0.14). Respirato-
ry failure was the most frequent reason for 
intubation in both groups. Overall, succi-
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nylcholine was the most commonly used 
neuromuscular blocking agent during RSI, 
and it produced no significant differences 
between the two groups. 
Comparison of outcomes
The overall 28-day mortality was 39%, as 
shown in table 3. The 28-day mortality of 
the ketamine group was not significantly 
different from that of the non-ketamine 
group (38% vs. 40%, respectively; P=0.78). 
The in-hospital LOS (ketamine group 
vs. non-ketamine group, 17 vs. 11 days; 
P=0.19) as well as the ICU LOS (ketamine 
group vs. non-ketamine group, 4 vs. 4 days; 
P=0.80) were not significantly different be-
tween the two groups. In addition, there 
was no significant difference between the 
two groups regarding the number of ven-
tilator days (ketamine group vs. non-keta-
mine group, 5 vs. 5 days; P=0.28). 








Age (years), median [IQ] 67 (55–74) 67 (57–73) 68 (53–75) 0.86
Gender (male), n (%) 103 (61) 60 (63) 43 (57) 0.44
BMI (kg/cm2), n (%) 0.73
  Under 29 (17) 18 (19) 11 (15)
  Normal 103 (61) 57 (60) 46 (61)
  Over 38 (22) 20 (21) 18 (24)
Comorbidities, n (%) 
  Hypertension 56 (33) 31 (33) 25 (33) 0.92
  Diabetes 21 (12) 13 (14) 8 (11) 0.55
  Cardiovascular disease 20 (12) 9 (9) 11 (15) 0.30
  Chronic lung disease 13 (8) 7 (7) 6 (8) 0.88
  Chronic renal disease 6 (4) 2 (2) 4 (5) 0.26
  Chronic hepatic disease 9 (5) 3 (3) 6 (8) 0.16
  Malignancy* 92 (54) 59 (62) 33 (44) 0.02
Infection focus, n (%) 0.92
  Intra-abdominal 35 (21) 20 (21) 15 (20)
  Respiratory 98 (58) 55 (58) 43 (57)
  Urinary tract 9 (5) 4 (4) 5 (7)
Wound/Soft tissue 10 (6) 6 (6) 4 (5)
CNS 1 (1) 0 (0) 1 (1)
Indwelling device 3 (2) 2 (2) 1 (1)
Other infections 14 (8) 8 (8) 6 (8)
Initial vital signs, median [IQ]
Mean arterial pressure* (mmHg) 66 (56–82) 61 (55–77) 69 (58–93) 0.02
Heart rate (beats per minute) 121 (102–138) 119 (105–137) 121 (99–140) 0.76
Respiratory rate (breaths per minute) 24 (20–32) 22 (20–32) 24 (20–32) 0.55
  Body temperature (ºC) 37.7 (36.5–38.7) 38.0 (36.9–38.8) 37.4 (36.4–38.6) 0.17
Initial serum lactate (mmol/l), median [IQ] 5.1 (3.5–7.1) 4.8 (3.3–7.0) 5.3 (3.7–7.8) 0.21
SOFA score, median [IQ] 9 (6–11) 9 (6–11) 9 (6–11) 0.70
APACHE II score, median [IQ] 20 (16–25) 20 (17–25) 20 (15–25) 0.69
Time to antibiotic* (min), median [IQ] 132 (91–187) 125 (83–171) 148 (95–224) <0.01
Steroid use, n (%) 84 (49) 52 (55) 32 (43) 0.12
Any vasopressor use before intubation*, n (%) 83 (49) 57 (60) 26 (35) <0.01
Vasopressor use within the first 7 days after admission 132 (78) 74 (78) 58 (73) 0.93
Data are shown as the median with interquartile range or as n (%).
P-values were calculated using the Wilcoxon rank sum test or the Pearson’s chi-square test. 
*P-value less than 0.05 
ALT, alanine aminotransferase; APACHE II score, Acute Physiology and Chronic Health Evaluation II score; AST, aspartate aminotrans-
ferase; INR, international normalized ratio; PT, prothrombin time; SOFA, Sequential Organ Failure Assessment.
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Multivariable analysis 
The results of multivariable analysis to pre-
dict ketamine use for endotracheal intuba-
tion are shown in table 4. Adjusted OR of 
initial mean arterial pressure was 0.98 (95% 
CI 0.960-0.996; P=0.02). Adjusted ORs of 
respiratory failure and shock were 10.08 
(95% CI 3.02-33.68; P<0.01) and 14.65 
(95% CI 2.93-73.22; P<0.01), respectively, 
compared to altered mental status. 
Multivariable analysis models to assess as-
sociations between ketamine use for intuba-
tion and 28-day mortality are shown in table 
5. The unadjusted OR of ketamine use for 
28-day mortality was 0.92 (95% CI: 0.49–
1.70; P=0.78). The association remained 
non-significant after adjusting for patient 
age, patient gender, malignancy, initial lac-
tate level on ED admission, time to first 
antibiotic administration and APACHE II 
score on admission day (adjusted OR: 1.01; 
95% CI: 0.51–2.01; P=0.97) (Model 1). The 
final models included the adjusting factors 
used in Model 1 and the propensity score 
regarding ketamine use. This model also 
demonstrated that ketamine use to facilitate 
intubation was not associated with 28-day 
mortality (adjusted OR: 1.09; 95% CI: 0.49–
2.40; P=0.84) (Model 2). The initial serum 
lactate value on ED admission was the only 
significant predicting factor of 28-day mor-
tality (adjusted OR: 1.23; 95% CI: 1.10–1.38; 
P<0.01). 








Vital signs and SPO2 before intubation, median [IQR]
Mean arterial pressure (mmHg) 77 (65–93) 77 (65–91) 78 (65–95) 0.58
Heart rate (beats per minute) 122 (110–137) 121 (110–135) 123 (108–140) 0.48
Respiratory rate (breaths per minute) 29 (24–35) 30 (25–35) 28 (22–35) 0.32
SPO2 (%) 92 (87–96) 93 (88–97) 90 (86–96) 0.17
Time to intubation (hour), median [IQR] 7.9 (3.1–23.2) 7.6 (3.6–25.9) 8.2 (1.5–22.1) 0.31
Reasons for intubation*, n (%) <0.01
  Altered mental status 28 (16) 4 (4) 24 (32)
  Respiratory failure 126 (74) 79 (83) 47 (62)
  Shock 16 (9) 12 (13) 4 (5)
Location of intubation*, n (%) <0.01
  ED 86 (51) 37 (39) 49 (65)
  ICU 84 (49) 58 (61) 26 (35)
Neuromuscular blocking agents, n (%) 0.55
  Succinylcholine 124 (73) 71 (75) 53 (71)
  Others† 46 (27) 24 (25) 22 (29)
Data are shown as the median with interquartile range or n (%).
P-values were calculated using the Wilcoxon rank sum test or the Pearson’s chi-square test. 
ED, emergency department; ICU, intensive care unit.
*P-value less than 0.05 
†Others: Vecuronium, Cisacuratriumracy percent was 77%, and area under the receiver operating characteristic curve for predicting 
ketamine use was 0.79. 
CI, confidence interval; ED, emergency department; ICU, intensive care unit; OR, odds ratio. 








28-day mortality, n (%) 66 (39) 36 (38) 30 (40) 0.78
In-hospital mortality, n (%) 79 (46) 43 (45) 36 (48) 0.72
In-hospital LOS (days), median [IQR] 15 (4–29) 17 (7–30) 11 (4–27) 0.19
ICU LOS (day), median [IQR] 4 (2–8) 4 (2–8) 4 (2–6) 0.80
Ventilator days, median [IQR] 5 (3–10) 5 (3–11) 5 (3–9) 0.28
Total vasopressor administration time  (hour), median [IQR] 28 (1–61) 31 (1–64) 26 (7–56) 0.67
Data are shown as the median with interquartile range or n (%).
P-values were calculated using the Wilcoxon rank sum test or the Pearson’s chi-square test. 
ICU, intensive care unit; LOS, length of stay. 
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Table 5. Associations between ketamine use for intubation and 28-day mortality in patients with severe sepsis or septic shock after adjust-
ments for potential confounding factors. 
OR 95% CI P-value
Model 1
Ketamine use 1.01 0.51-2.01 0.97
Patient age 1.00 0.98-1.03 0.99
Patient gender 0.98 0.49-1.96 0.96
Malignancy 1.90 0.92-3.89 0.08
Initial lactate level* 1.23 1.10-1.37 <0.01
Time to antibiotic administration† 1.07 0.95-1.20 0.28
Initial APACHE II score 0.99 0.95-1.04 0.83
Model 2
Ketamine use 1.09 0.49-2.40 0.84
Patient age 1.00 0.97-1.02 0.95
Patient gender 0.98 0.49-1.95 0.95
Malignancy 1.98 0.93-4.23 0.08
Initial lactate level* 1.23 1.10-1.38 <0.01
Time to antibiotic administration† 1.06 0.94-1.19 0.37
Initial APACHE II score 0.99 0.95-1.04 0.81
  Propensity score regarding ketamine use 0.74 0.14-4.03 0.73
*P-value less than 0.05 
†Time from emergency department arrival until initiation of the first antibiotic administration
The goodness-of-fit of the final model I was 0.34 with the Hosmer-Lemeshow test and 0.15 with Nagelkerke’s R2. Classification accuracy 
percent was 72%, and area under the receiver operating characteristic curve (AUROC) for predicting 28-day mortality of Model I was 
0.67. 
The goodness-of-fit of the final model II was 0.31 with the Hosmer-Lemeshow test and 0.15 Nagelkerke’s R2. Classification accuracy 
percent was 71%, and AUROC for predicting 28-day mortality of Model II was 0.68. 
APACHE II score, Acute Physiology and Chronic Health Evaluation II score; CI, confidence interval; OR, odds ratio.
Table 4. Multivariable analysis to predict ketamine use for endotracheal intubation in patients with severe sepsis or septic shock.
OR 95% CI P-value
Malignancy 1.69 0.82-3.48 0.15
Initial mean arterial pressure*  0.98 0.960-0.996 0.02
Any vasopressor use before intubation 1.62 0.72-3.65 0.24
Time to antibiotic administration 0.88 0.75-1.04 0.13
Location of intubation
ED Reference
ICU 0.55 0.25-1.22 0.14
Reasons for intubation
 Altered mental status Reference
Respiratory failure* 10.08 3.02-33.68 <0.01
 Shock* 14.65 2.93-73.22 <0.01
*P-value less than 0.05 
†Time from emergency department arrival until initiation of the first antibiotic administration
The goodness-of-fit of the model was 0.23 with the Hosmer-Lemeshow test and 0.34 with Nagelkerke’s R2. Classification accu
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DISCUSSION
In this study, we observed that ketamine 
use for RSI in patients with severe sepsis 
or septic shock did not influence 28-day 
mortality compared to alternative agents. 
Furthermore, we found no significant dif-
ferences in any secondary measures, in-
cluding ventilator days, ICU LOS, hospital 
LOS and in-hospital mortality, according 
to the use of any sedatives. 
Ketamine is the only currently available 
sedative comparable to etomidate that is 
associated with favorable hemodynamic 
profiles. Several studies have demonstrated 
the usefulness of ketamine as a sedative 
agent in many different fields. Patanwala 
et al. investigated first-pass success intu-
bation in patients who received etomidate 
or ketamine for RSI performed in the ED. 
They showed that first-pass success intuba-
tion was equivalent despite any use of keta-
mine or etomidate in the ED. However, 
outcomes regarding morbidity or mortal-
ity were not described. (15) Ballow et al. 
developed a standardized RSI medication 
protocol for trauma patients who require 
ED intubation at a level I trauma center. 
(16) Ketamine was incorporated into the 
protocol as a sedative agent for RSI. The 
authors concluded that the use of ketamine 
was effective in critically injured patients, 
even those with traumatic brain injury. 
Price et al. assessed the hemodynamics be-
fore and after ketamine use for prehospital 
intubation in the air medical setting. In 
their study, ketamine use was not associat-
ed with any adverse hemodynamic param-
eter changes compared to etomidate. (17) 
Although ketamine has been used as a 
main intubation drug for many years, 
there are discrepancies between real world 
practices and supporting evidence for the 
use of ketamine for RSI in septic patients 
with hemodynamic instability. Only a few 
studies have specifically investigated the 
impact of ketamine on outcome in such 
septic patients. Jabre et al. prospectively 
evaluated 655 critically ill patients, includ-
ing injured, stroke, and septic patients, 
who received either etomidate or ketamine 
for intubation. They showed that a single 
dose of etomidate was not associated with 
increased morbidity or mortality com-
pared to ketamine. In a subgroup analysis 
of septic patients (n=76), there were also 
no significant differences in outcomes be-
tween etomidate and ketamine use. Jabre 
et al. suggested that ketamine is safe and 
offers a good alternative to etomidate for 
intubation in septic patients. However, 
they also stated that this finding could only 
be attributed to their small number of in-
cluded septic patients. Our data provide 
additional evidence to support the use of 
ketamine in patients with severe sepsis or 
septic shock. In patients with severe sepsis 
or septic shock, ketamine use as a part of 
RSI has not been shown to increase 28-day 
mortality compared to those who received 
alternative sedatives. Other outcomes, 
including ventilator days, ICU LOS and 
in-hospital LOS, which are important out-
comes associated with preventing hospital-
acquired infections and reducing hospital 
costs, were also not different according to 
the use of any sedatives. 
Ketamine has potential advantages over al-
ternative sedatives, which makes it attrac-
tive for patients with severe sepsis or septic 
shock. First, ketamine does not affect adre-
nal function, which is the main drawback 
of etomidate use in septic patients. Second, 
ketamine increases catecholamine concen-
trations and stimulates the sympathetic 
nervous system; as a result, it increases 
blood pressure and systemic vascular re-
sistance in patients without catecholamine 
depletion. As septic patients are at greater 
risk of hemodynamic deterioration, this 
characteristic might be a valuable prop-
erty. However, one should be cautious, 
as the direct negative inotropic effects of 
ketamine on the myocardium might out-
weigh the indirect sympathetic stimulating 
effects in patients with severely prolonged 
shock or catecholamine depletion, result-
ing in hemodynamic deterioration or even 
cardiac arrest. (18) Finally, in vitro and 
animal studies have suggested that keta-
mine acts as a protective modulator of pro-
inflammatory cytokines, such as TNF-a, 
IL-1β, and IL-6. (19,20) A previous limited 
study performed in post-operative patients 
also showed that ketamine inhibited se-
rum IL-6 and superoxide anions produced 
by neutrophils. (21,22) However, the im-
pact of these properties of ketamine on 
the outcome of septic patients is still not 
confirmed and well-designed studies will 
be required to establish the clear role of 
ketamine in septic patients. 
The results of a multiple logistic regression 
analysis in this study revealed that elevated 
serum lactate on ED admission was the 
only significant factor that predicted 28-
day mortality in patients with severe sepsis 
or septic shock who were intubated using 
RSI. Despite its limitations, serum lactate 
has been widely used in the field of sepsis 
care, such as for identifying tissue hypop-
erfusion and assessing the severity of sep-
sis and resuscitation endpoints. (14,23,24) 
Our finding reinforces the importance of 
the early measurement of serum lactate, as 
recommended by international guidelines. 
(25) This parameter will help clinicians 
identify patients at higher risk for death; 
we suggest providing a more aggressive 
management to reduce the mortality in 
septic patients with an elevated serum lac-
tate level on ED arrival. 
There are several limitations to this study 
that should be considered. First,  it was a 
retrospective,single-center study and is 
therefore limited to other settings in its 
generalizability. Second, the selection of 
drugs was entirely dependent on the oper-
ator’s preference, which might have caused 
a selection bias. Third, the study popula-
tion included patients with severe sepsis 
or septic shock, producing heterogeneity 
in the patient characteristics. However, we 
only selected patients with severe sepsis 
who had a serum lactate level greater than 
4 mmol/l, which indicates cryptic shock. 
Puskarich et al. showed that mortality in 
severe sepsis with an elevated serum lac-
tate (≥ 4 mmol/l) was comparable to that of 
overt septic shock. (26) Recently published 
data from the Surviving Sepsis Campaign 
database also indicated that patients with 
a lactate level greater than 4 mmol/l were 
significantly associated with in-hospital 
mortality regardless of the presence of hy-
potension. (27) 
CONCLUSION
For patients with severe sepsis or septic 
shock who were intubated using RSI, we 
found no significant difference in 28-day 
mortality between those who received ket-
amine as a sedative agent and those who 
received alternative sedatives.
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